WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

V VARIOUS

This group comprises many different types of drugs, and assigning DDDs are difficult. Very few DDDs are assigned in this group.


V09 DIAGNOSTIC RADIOPHARMACEUTICALS

An expert group has been responsible for the ATC classification of radiopharmaceuticals in V09 and V10. The group has also prepared the guidelines for classification of these products.
Radiopharmaceuticals for diagnostic use are classified in this group, while radiopharmaceuticals for therapeutic use are classified in V10. In general, the 3rd level are subdivided according to site of action or organ system, the 4th level according to radionuclide and the 5th level specifies the chemical substance. The ATC 5th level defines the actual form essential in nuclear medicine procedures, which includes radionuclide and carrier molecule. Therefore, products on the market, that can often be regarded as intermediate products rather than ready-to-use radiopharmaceuticals, can be given more than one (5th level) ATC code, e.g. technetium (99mTc) exametazime (V09AA01) and technetium (99mTc) exametazime labelled cells (V09HA02).
ATC codes are not assigned for radionuclide precursors which are used only in the radiolabelling of another substance prior to administration.

No DDDs have been assigned for radiopharmaceuticals.


V09A CENTRAL NERVOUS SYSTEM

This group comprises preparations used in CNS investigations in diagnostic nuclear medicine.


V09AA Technetium (99mTc) compounds
V09AB Iodine (123I) compounds
V09AX Other central nervous system diagnostic radiopharmaceuticals

Last updated: 2024-01-26